FI115631B - Uudet kinuklidiinijohdannaiset ja niiden lääkekoostumus - Google Patents

Uudet kinuklidiinijohdannaiset ja niiden lääkekoostumus Download PDF

Info

Publication number
FI115631B
FI115631B FI972775A FI972775A FI115631B FI 115631 B FI115631 B FI 115631B FI 972775 A FI972775 A FI 972775A FI 972775 A FI972775 A FI 972775A FI 115631 B FI115631 B FI 115631B
Authority
FI
Finland
Prior art keywords
tetrahydro
group
quinuclidinyl
isoquinolinecarboxylate
compound
Prior art date
Application number
FI972775A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI972775A0 (fi
FI972775A (fi
Inventor
Yasuo Isomura
Makoto Takeuchi
Ryo Naito
Masahiko Hayakawa
Yoshinori Okamoto
Yasuhiro Yonetoku
Ken Ikeda
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18194699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI115631(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of FI972775A0 publication Critical patent/FI972775A0/fi
Publication of FI972775A publication Critical patent/FI972775A/fi
Application granted granted Critical
Publication of FI115631B publication Critical patent/FI115631B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06—Non-steroidal liquid crystal compounds
    • C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
    • C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Tea And Coffee (AREA)
  • Liquid Crystal Substances (AREA)
FI972775A 1994-12-28 1997-06-27 Uudet kinuklidiinijohdannaiset ja niiden lääkekoostumus FI115631B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP32704594 1994-12-28
JP32704594 1994-12-28
JP9502713 1995-12-27
PCT/JP1995/002713 WO1996020194A1 (fr) 1994-12-28 1995-12-27 Nouveaux derives de quinuclidine et composition pharmaceutique les contenant

Publications (3)

Publication Number Publication Date
FI972775A0 FI972775A0 (fi) 1997-06-27
FI972775A FI972775A (fi) 1997-08-22
FI115631B true FI115631B (fi) 2005-06-15

Family

ID=18194699

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972775A FI115631B (fi) 1994-12-28 1997-06-27 Uudet kinuklidiinijohdannaiset ja niiden lääkekoostumus

Country Status (24)

Country Link
US (2) US6017927A (ja)
EP (1) EP0801067B1 (ja)
JP (1) JP3014457B2 (ja)
KR (1) KR100386487B1 (ja)
CN (1) CN1045601C (ja)
AT (1) ATE233761T1 (ja)
AU (1) AU695616B2 (ja)
CA (1) CA2208839C (ja)
DE (2) DE69529844T2 (ja)
DK (1) DK0801067T3 (ja)
ES (1) ES2193208T3 (ja)
FI (1) FI115631B (ja)
FR (1) FR04C0032I2 (ja)
HU (1) HU223778B1 (ja)
LU (1) LU91133I9 (ja)
MX (1) MX9704880A (ja)
NL (1) NL300141I2 (ja)
NO (4) NO2005012I1 (ja)
NZ (1) NZ298144A (ja)
PL (1) PL182344B1 (ja)
PT (1) PT801067E (ja)
RU (1) RU2143432C1 (ja)
TW (1) TW305842B (ja)
WO (1) WO1996020194A1 (ja)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
FR2772378B1 (fr) * 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
JP2001316670A (ja) * 2000-05-02 2001-11-16 Dainippon Ink & Chem Inc 液晶組成物
DE20122417U1 (de) * 2000-06-27 2005-08-04 Laboratorios S.A.L.V.A.T., S.A., Esplugues De Llobregat Von Arylalkylaminen abgeleitete Carbamate
JP4445704B2 (ja) * 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
UA75626C2 (en) 2000-12-28 2006-05-15 Almirall Prodesfarma Ag Quinuclidine derivatives and medicinal compositions containing the same
JP4174673B2 (ja) 2001-07-10 2008-11-05 アステラス製薬株式会社 間質性膀胱炎治療用医薬組成物
CN1832948B (zh) * 2001-12-20 2011-06-15 基耶西药品股份公司 1-烷基-1-氮*双环[2.2.2]辛烷氨基甲酸酯衍生物及其用作蕈毒碱受体拮抗剂的用途
EP1552825A4 (en) * 2002-06-07 2009-11-25 Astellas Pharma Inc THERAPEUTIC AGENT FOR THE TREATMENT OF VESIC HYPERACTIVITY
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
DE60230683D1 (de) 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
DE60226906D1 (de) 2002-07-31 2008-07-10 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen
US7410993B2 (en) 2002-08-09 2008-08-12 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives useful as muscarinic receptor antagonists
DE60231341D1 (de) 2002-08-23 2009-04-09 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
MXPA05003398A (es) * 2002-10-29 2005-06-22 Pharmacia & Upjohn Co Llc Compuestos de amonio cuaternario.
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
AU2003301184A1 (en) * 2002-12-20 2004-07-22 Dynogen Pharmaceuticals Inc METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS
WO2004056811A1 (en) * 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
EP1583741A1 (en) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
EP1618091A1 (en) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1615887A1 (en) 2003-04-10 2006-01-18 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
ATE362364T1 (de) 2003-04-10 2007-06-15 Ranbaxy Lab Ltd Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
CN100436414C (zh) 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
WO2005075474A1 (ja) * 2004-02-09 2005-08-18 Astellas Pharma Inc. コハク酸ソリフェナシン含有組成物
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
JPWO2005087231A1 (ja) * 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
EP1726304A4 (en) * 2004-03-16 2010-04-28 Astellas Pharma Inc COMPOSITION CONTAINING SOLIFENACIN
EP1728791A4 (en) * 2004-03-25 2008-12-10 Astellas Pharma Inc COMPOSITIONS FOR SOLID PHARMACEUTICAL PREPARATION OF SOLIFENACIN OR BZW. A SALT OF IT
ZA200608614B (en) * 2004-03-25 2008-06-25 Astellas Pharma Inc Composition for solid pharmaceutical preparation of solifenacin or salt thereof
WO2006035280A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
EP1797040A1 (en) * 2004-09-29 2007-06-20 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP1832288B1 (en) 2004-12-27 2012-06-20 Astellas Pharma Inc. Stable granular pharmaceutical composition of solifenacin or its salt
MX2007007911A (es) * 2004-12-27 2007-08-20 Astellas Pharma Inc Composicion farmaceutica granular estable de solifenacina o su sal.
EP1852117A4 (en) * 2005-02-25 2010-10-27 Astellas Pharma Inc PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
WO2007007281A2 (en) * 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
JP2008535931A (ja) * 2005-12-21 2008-09-04 テバ ファーマシューティカル インダストリーズ リミティド ソリフェナシンの調製方法
CZ300699B6 (cs) 2006-06-21 2009-07-22 Zentiva, A. S. Zpusob prípravy solifenacinu
WO2008011462A2 (en) * 2006-07-19 2008-01-24 Dr. Reddy's Laboratories Ltd. Process for preparing solifenacin and its salts
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
US20080114028A1 (en) * 2006-07-24 2008-05-15 Tamas Koltai Process for preparing polymorphic forms of solifenacin succinate
WO2008019055A2 (en) * 2006-08-03 2008-02-14 Teva Pharmaceutical Industries Ltd. Processes for optical resolution of 1-phenyl-1,2,3,4-tetrahydroisoquinoline
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
EP2102200A2 (en) * 2006-11-22 2009-09-23 Medichem, S.A. An improved process for the synthesis of solifenacin
CZ300692B6 (cs) * 2006-12-22 2009-07-15 Zentiva, A. S. Zpusob prípravy solifenacinu
CN101711248A (zh) * 2007-03-30 2010-05-19 医药化学公司 一种改进的素非那新合成工艺
EP2146693A2 (en) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
JP2009538362A (ja) * 2007-07-13 2009-11-05 テバ ファーマシューティカル インダストリーズ リミティド ソリフェナシンの調製方法
CA2697137A1 (en) * 2007-07-20 2009-01-29 Astellas Pharma Inc. Pharmaceutical composition for amelioration of lower urinary tract symptoms associated with prostatomegaly
EP2018850A1 (en) * 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
SI2216021T1 (sl) * 2007-11-02 2013-01-31 Astellas Pharma Inc. Farmacevtski sestavek za zdravljenje prekomerno aktivnega sečnega mehurja
JP2011505416A (ja) * 2007-12-04 2011-02-24 カディラ ヘルスケア リミティド 化学的及びキラル的に純粋なソリフェナシン塩基及びその塩を調製する方法
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
ITMI20080195A1 (it) 2008-02-08 2009-08-09 Dipharma Francis Srl Procedimento per la preparazione di solifenacin
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CA2718411C (en) 2008-03-27 2016-02-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
PL385264A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
SI3067353T1 (en) 2008-07-29 2018-03-30 Krka, D.D., Novo Mesto Process for the preparation of solifenacin salts and their inclusion in pharmaceutical dosage forms
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
NZ594311A (en) * 2009-02-04 2013-05-31 Astellas Pharma Inc Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
EP2406257B1 (en) 2009-03-09 2019-08-07 Megafine Pharma (P) Ltd. A new method for the preparation of solifenacin and new intermediate thereof
US20100273825A1 (en) * 2009-03-30 2010-10-28 Astellas Pharma Inc. Solid pharmaceutical composition containing solifenacin amorphous form
WO2011048607A1 (en) * 2009-09-25 2011-04-28 Cadila Healthcare Limited Processes for the preparation of solifenacin or a salt thereof
PL234208B1 (pl) 2010-01-18 2020-01-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób wytwarzania bursztynianu solifenacyny
ES2604705T3 (es) 2010-03-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Agente preventivo y/o remedio para el síndrome mano-pie
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
HUE029400T2 (en) 2010-05-19 2017-03-28 Astellas Pharma Inc Pharmaceutical composition containing Solifenacin
US8772491B2 (en) 2010-06-28 2014-07-08 Aurobindo Pharma Ltd Process for the preparation of solifenacin succinate
EP2590973B1 (en) 2010-07-05 2016-08-31 Crystal Pharma, S.A.U. Solifenacin salts
WO2012062916A1 (de) 2010-11-11 2012-05-18 Hexal Ag Kristallines solifenacin-succinat
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN103813792B (zh) 2011-05-10 2015-11-25 塞拉维达公司 用于治疗膀胱过度活动症的索利那新和唾液刺激剂的组合
JP2014520126A (ja) 2011-06-22 2014-08-21 イソケム ソリフェナシンおよびその塩の製造方法
KR101365849B1 (ko) 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
WO2014005601A1 (en) 2012-07-02 2014-01-09 Pharmathen S.A. A process for the preparation of solifenacin or a salt thereof
EA201590449A1 (ru) 2012-08-31 2015-06-30 Астеллас Фарма Инк. Перорально вводимая лекарственная композиция
BR112015004902A2 (pt) 2012-09-05 2017-07-04 Chase Pharmaceuticals Corp métodos e composição neutroprotetores anticolinérgicos
CN103787969B (zh) 2012-10-30 2016-07-06 上海京新生物医药有限公司 一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法
CA2893627C (en) * 2012-12-06 2021-09-14 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2778167A1 (en) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
BR112016000629B1 (pt) * 2013-07-13 2023-10-31 Beijing Showby Pharmaceutical Co., Ltd. Compostos de quinina e isômeros ópticos, método de preparação e utilização médica dos mesmos
EP3139924A4 (en) 2014-05-06 2018-03-07 Anthony G. Visco Methods of treating or preventing preterm labor
CN104592221A (zh) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 一种合成索非那新的工艺
KR20160146428A (ko) 2015-06-12 2016-12-21 한미정밀화학주식회사 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
KR102148414B1 (ko) 2017-05-15 2020-08-26 주식회사 서울제약 솔리페나신을 유효성분으로 하는 구강붕해필름
WO2019118528A1 (en) * 2017-12-12 2019-06-20 Arkuda Therapeutics Progranulin modulators and methods of using the same
AU2020290485A1 (en) * 2019-06-12 2021-12-02 Arkuda Therapeutics Progranulin modulators and methods of using the same
CN113200979A (zh) * 2021-04-13 2021-08-03 上海予君生物科技发展有限公司 一种琥珀酸索非那新的合成工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247266B1 (en) * 1986-01-07 1993-03-10 Beecham Group Plc Indole derivatives having an azabicyclic side chain, process for their preparation, intermediates, and pharmaceutical compositions
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
JPH076635A (ja) * 1993-06-18 1995-01-10 Sony Corp 信号伝送ケーブル
WO1995006635A1 (fr) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
DE60308296T2 (de) * 2002-11-27 2007-09-06 Selmac S.R.L., Vigevano Vorrichtung zum Positionieren und Spannen geformter Teile und damit ausgerüstete Maschine

Also Published As

Publication number Publication date
CN1171109A (zh) 1998-01-21
FR04C0032I2 (fr) 2005-10-21
MX9704880A (es) 1997-10-31
ES2193208T3 (es) 2003-11-01
PT801067E (pt) 2003-07-31
NL300141I1 (nl) 2004-04-01
EP0801067A1 (en) 1997-10-15
KR100386487B1 (ko) 2003-09-26
WO1996020194A1 (fr) 1996-07-04
PL321019A1 (en) 1997-11-24
US6017927A (en) 2000-01-25
DE122004000048I2 (de) 2006-02-02
LU91133I2 (fr) 2005-03-29
PL182344B1 (pl) 2001-12-31
NO2005016I1 (no) 2005-08-29
KR987000303A (ko) 1998-03-30
DE122004000048I1 (de) 2005-04-21
US6174896B1 (en) 2001-01-16
AU4355396A (en) 1996-07-19
FI972775A0 (fi) 1997-06-27
JP3014457B2 (ja) 2000-02-28
NZ298144A (en) 1998-04-27
AU695616B2 (en) 1998-08-20
HUT77006A (hu) 1998-03-02
DE69529844D1 (de) 2003-04-10
NO318026B1 (no) 2005-01-24
FR04C0032I1 (ja) 2005-02-11
EP0801067A4 (en) 1998-03-11
NO2017055I2 (no) 2017-11-06
LU91133I9 (en) 2018-08-01
CN1045601C (zh) 1999-10-13
NO2017055I1 (no) 2017-11-06
TW305842B (ja) 1997-05-21
DE69529844T2 (de) 2004-03-04
RU2143432C1 (ru) 1999-12-27
CA2208839A1 (en) 1996-07-04
DK0801067T3 (da) 2003-06-30
CA2208839C (en) 2006-01-31
HU223778B1 (hu) 2005-01-28
EP0801067B1 (en) 2003-03-05
NO973027L (no) 1997-08-28
NO973027D0 (no) 1997-06-27
NO2005012I1 (no) 2005-06-06
ATE233761T1 (de) 2003-03-15
NO2005016I2 (no) 2008-02-11
JPH09508401A (ja) 1997-08-26
NL300141I2 (nl) 2004-04-01
FI972775A (fi) 1997-08-22

Similar Documents

Publication Publication Date Title
FI115631B (fi) Uudet kinuklidiinijohdannaiset ja niiden lääkekoostumus
Clark et al. 2-(Quinuclidin-3-yl) pyrido [4, 3-b] indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists
AU2003226579B2 (en) Azabicyclo derivatives as muscarinic receptor antagonists
JPH11502861A (ja) サブスタンスｐアンタゴニストとしての置換ベンゾラクタム化合物
KR20100068290A (ko) 알츠하이머병의 치료를 위한 알파 7 니코틴 아세틸콜린 수용체 리간드로서 퀴누클리딘-4-일메틸 1ｈ-인돌-3-카르복실레이트 유도체
WO1993016048A1 (en) Substituted acetamide compound
JP2002030084A (ja) １−アザビシクロアルカン化合物およびその医薬用途
JP2674199B2 (ja) 二環式アミン化合物およびその製造法
RU2418794C2 (ru) ПРОИЗВОДНЫЕ ИЗОХИНОЛИНА И БЕНЗО[h]ИЗОХИНОЛИНА, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА ГИСТАМИНА H3
KR100241662B1 (ko) 히드로이소퀴놀린 유도체
WO1998051671A1 (en) Substituted tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
CA1321996C (en) Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds
HUT54151A (en) Process fopr producing new (r)-(-)-3-quinuclidinone derivatives and pharmaceutical compositions comprising such compounds
US20030158222A1 (en) 2-3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (an-tipsychotic agents)
US6358974B1 (en) Isoquinoline derivatives
JPH0940646A (ja) ベンゼン縮合環誘導体又はその塩
JPH0240381A (ja) 新規縮合ジアゼピノン類、それらの製造方法及びこれらの化合物を含有する医薬組成物
CN101597260A (zh) 新的毒蕈碱受体拮抗剂及其用途
EP1086095B1 (en) Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
JP2003081978A (ja) スピロ環式化合物およびその医薬用途
NO168586B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepinon-forbindelser
JP3007675B2 (ja) 新規なインドール誘導体
PAIN United States Patent po
US20030191314A1 (en) Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors
KR20050023401A (ko) 무스카린 수용체 길항제로서 사용가능한 3,6-이치환된아자비시클로 [3.1.0]헥산 유도체

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115631

Country of ref document: FI

SPCF Supplementary protection certificate application filed
PC Transfer of assignment of patent

Owner name: ASTELLAS PHARMA INC.

Free format text: ASTELLAS PHARMA INC.

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 272

Extension date: 20181216

MA Patent expired
SPCE Application for extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: L20050024

SPCX Supplementary protection certificate: correction

Spc suppl protection certif: 272

Extension date: 20190622